Search research articles
Contact Us
Filters
Showing results (81-90 of 131) with videos related to
Page
of 14
Sort By:
Leukemia Research
|
February 27, 2022
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803]
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
ESMO Open
|
July 24, 2025
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications
G Griguolo, M V Dieci, S Fineberg, et al.
The Oncologist
|
November 15, 2017
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, et al.
Leukemia Research
|
February 12, 2022
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
NPJ Breast Cancer
|
December 24, 2025
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications
Gaia Griguolo, Michele Bottosso, Laia Paré, et al.
Frontiers in Oncology
|
June 28, 2019
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
Maria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, M V Dieci, G Bisagni, et al.
Cancer Medicine
|
October 8, 2022
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC"
Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, et al.
Ebiomedicine
|
November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Valentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
Federica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 131) with videos related to
Sort By:
Page
of 14
Leukemia Research
|
February 27, 2022
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803]
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
ESMO Open
|
July 24, 2025
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications
G Griguolo, M V Dieci, S Fineberg, et al.
The Oncologist
|
November 15, 2017
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, et al.
Leukemia Research
|
February 12, 2022
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
NPJ Breast Cancer
|
December 24, 2025
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications
Gaia Griguolo, Michele Bottosso, Laia Paré, et al.
Frontiers in Oncology
|
June 28, 2019
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
Maria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, M V Dieci, G Bisagni, et al.
Cancer Medicine
|
October 8, 2022
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC"
Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, et al.
Ebiomedicine
|
November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Valentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
Federica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
Page
of 14